Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a ch… Read more
Market Cap & Net Worth: Sangamo Therapeutics Inc (SGMO)
Sangamo Therapeutics Inc (NASDAQ:SGMO) has a market capitalization of $133.81 Million ($133.81 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17499 globally and #6617 in its home market, demonstrating a -13.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sangamo Therapeutics Inc's stock price $0.36 by its total outstanding shares 371684781 (371.68 Million).
Sangamo Therapeutics Inc Market Cap History: 2015 to 2026
Sangamo Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $3.39 Billion to $133.81 Million (-24.26% CAGR).
Index Memberships
Sangamo Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.01% | #475 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #1624 of 3165 |
Weight: Sangamo Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sangamo Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sangamo Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.56x
Sangamo Therapeutics Inc's market cap is 6.56 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.39 Billion | $39.54 Million | -$40.70 Million | 85.83x | N/A |
| 2016 | $1.13 Billion | $19.39 Million | -$71.66 Million | 58.47x | N/A |
| 2017 | $6.10 Billion | $36.57 Million | -$54.57 Million | 166.70x | N/A |
| 2018 | $4.27 Billion | $84.45 Million | -$68.33 Million | 50.53x | N/A |
| 2019 | $3.11 Billion | $102.43 Million | -$75.82 Million | 30.37x | N/A |
| 2020 | $5.80 Billion | $118.19 Million | -$121.12 Million | 49.07x | N/A |
| 2021 | $2.79 Billion | $110.70 Million | -$178.30 Million | 25.18x | N/A |
| 2022 | $1.17 Billion | $111.30 Million | -$192.28 Million | 10.49x | N/A |
| 2023 | $201.94 Million | $176.23 Million | -$257.83 Million | 1.15x | N/A |
| 2024 | $379.12 Million | $57.80 Million | -$97.94 Million | 6.56x | N/A |
Competitor Companies of SGMO by Market Capitalization
Companies near Sangamo Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Sangamo Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Sangamo Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Sangamo Therapeutics Inc's market cap moved from $3.39 Billion to $ 133.81 Million, with a yearly change of -24.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $133.81 Million | -14.29% |
| 2025 | $156.11 Million | -58.82% |
| 2024 | $379.12 Million | +87.74% |
| 2023 | $201.94 Million | -82.70% |
| 2022 | $1.17 Billion | -58.13% |
| 2021 | $2.79 Billion | -51.94% |
| 2020 | $5.80 Billion | +86.44% |
| 2019 | $3.11 Billion | -27.09% |
| 2018 | $4.27 Billion | -30.00% |
| 2017 | $6.10 Billion | +437.70% |
| 2016 | $1.13 Billion | -66.59% |
| 2015 | $3.39 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Sangamo Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $133.81 Million USD |
| MoneyControl | $133.81 Million USD |
| MarketWatch | $133.81 Million USD |
| marketcap.company | $133.81 Million USD |
| Reuters | $133.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.